We Bring Innovation to Healthcare

Antiphospholipid Syndrome

Antiphospholipid Syndrome (APS), also known as Hughes syndrome is an autoimmune disease defined by the development of venous and/or arterial thrombosis, often multiple, and pregnancy morbidity.


Endotelix is fully focused on innovation within the field of antiphospholipid syndrome. As such, our pipeline is centred on two main clinical developmental projects.


These projects, which include diagnostics and treatments, will significantly improve the management of APS and therefore the lives of the patients who suffer from it.


Endotelix offers fast, reliable and specific solutions for clinical APS management, including diagnostic tools and treatments.



Endotelix is a privately held Swiss biotech start-up company and a spin-off from the University of Geneva. Endotelix is dedicated to providing fast, sensitive and reliable solutions for Antiphospholipid Syndrome including diagnostic tests and treatment options.



Endotelix Diagnostics Sàrl

Chemin des Aulx, 14

CH-1228 Plan-les-Ouates


Tel: +41 (0)22 880 1010

Geneva, Switzerland

Vos informations ont bien été envoyées !